Physician profile
Kirit S Patel
NPI 1477512309
$37,246.34
in general payments reported to CMS, 2019-2025
22 companies · $540 in 2025
The $540 reported for 2025 was more than what 79% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,444 · 2020: $10K · 2021: $13K · 2022: $2,091 · 2023: $2,218 · 2024: $1,785 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,544.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $19,888.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $12,518.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Daiichi Sankyo INC. | $2,333.48 | 2020-2024 | Injectafer |
| Novo Nordisk INC | $710.79 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $644.64 | 2021-2023 | Repatha |
| Phathom Pharmaceuticals, INC. | $184.96 | 2025 | Voquezna |
| Mylan Specialty L.P. | $142.55 | 2021-2023 | Yupelri |
| Biodelivery Sciences International, INC. | $134.23 | 2019-2020 | |
| Esperion Therapeutics, INC. | $125.00 | 2022 | |
| Smith+Nephew, INC. | $124.46 | 2019 | |
| Pfizer INC. | $104.31 | 2024 | |
| Novartis Pharmaceuticals Corporation | $73.47 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $48.98 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $37.24 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.52 | 2023 | Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $29.52 | 2025 | Artix Mt |
| Alpha Cognition USA, INC. | $27.59 | 2025 | Zunveyl |
| Sage Therapeutics, LLC | $22.13 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $18.57 | 2025 | Cobenfy |
| Alkermes, INC. | $16.36 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.